Navigation Links
Enigma Signs Real-Time PCR Licences With Applera
Date:2/7/2008

PORTON DOWN, England, February 7 /PRNewswire/ -- Enigma Diagnostics, the life sciences company developing rapid molecular diagnostics systems, announces today that it has signed license agreements with Applera Corporation.

The licenses, signed 6 February 2008, include a Real-Time Instrument Patent License Agreement and an Application Kit License Agreement. These agreements provide Enigma with access under patents owned or controlled by Applera for real-time PCR thermal cyclers and real-time PCR methods and compositions in specific fields.

The Real-Time Instrument Patent License Agreement covers Enigma's current and pipeline instrument platforms of fully automated, real-time thermal cyclers across the commercial market sectors of research and applied markets. This agreement also provides Enigma with an option for a license in clinical diagnostics.

The Application Kit License Agreement covers a portfolio of important patents covering reverse transcription-based methods, real-time PCR detection process and 5' Nuclease assays and compositions, for use in fields excluding human diagnostics.

Financial terms were not disclosed.

John McKinley, Chairman of Enigma Diagnostics, said: "These licenses together with Enigma's extensive portfolio of molecular diagnostic patents and unique instrument platforms confirm Enigma's leading position within the global molecular diagnostics market and underpin the launch of its instruments in 2008."

Notes to Editors:

About Enigma Diagnostics

Enigma Diagnostics Limited is a private UK based company developing the next generation of rapid diagnostic instrument platforms for the detection and identification of infectious organisms, such as bacteria and viruses, in clinical, environmental and biological samples.

Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for field-based and point-of-care tests. The Company is targeting a number of multi-billion pound markets, core among which are the clinical, defence and homeland security, and veterinary markets. Enigma's commercialisation strategy is to maximise revenues from a continuous flow of market leading rapid diagnostic point-of-care and in-field instrument and assay platforms, derived from its broad Intellectual Property portfolio of issued and filed patents. Enigma will build an in-house sales and marketing capability to direct distribution of its bespoke products and partner with market leaders where global penetration of markets is required.

Enigma has an exclusive license from the Defence Science Technology Laboratory to a portfolio of patents which represent over 15 years of UK Ministry of Defence funded research. Enigma's own R&D activities have added additional patents and design rights based upon its proprietary technologies to generate a portfolio of over 45-plus worldwide patents and patent applications dedicated to real-time PCR and wider rapid technologies of which over 26 have granted status. The patents are granted in a range of core territories. Information about Enigma is available at http://www.enigmadiagnostics.com


'/>"/>
SOURCE Enigma Diagnostics Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
2. Enigma Diagnostics to Develop Clinical Diagnostics Platform for UK National Chlamydia Screening Programme
3. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
6. Monsanto Company Signs Share Subscription Agreement With Devgen
7. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
8. Shandong Zhouyuan Seed and Nursery Co., Ltd. Signs an Agreement with Linyi Company
9. Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge
10. Assay Designs(TM) Announces Additions to the Leadership Team
11. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... IN (PRWEB) , ... June 23, 2017 , ... ... voice for model aircraft flying hobbyists, and the University Aviation Association (UAA), the ... college students. The UAS4STEM Collegiate Challenge will encourage teamwork, competition, and success through ...
(Date:6/22/2017)... ... June 22, 2017 , ... Ovation Fertility supports ... a disease, bringing new hope for prospective parents who are challenged with costs ... back the World Health Organization’s designation in hopes of changing the way health ...
(Date:6/22/2017)... Lawrence, MA (PRWEB) , ... June 22, 2017 , ... ... completed ILVO validation. The AMPH test was determined to be appropriate as a screening ... for visual interpretation, on the Charm EZ system, and the Charm EZ Lite system. ...
(Date:6/20/2017)... ... June 20, 2017 , ... National executive ... leader with extensive assay development and biomarker expertise, as VP of Scientific Affairs ... CRO specializing in bio-analytical assay development and sample testing services. The organization acts ...
Breaking Biology Technology:
(Date:3/22/2017)... March 21, 2017 Optimove , ... by retailers such as 1-800-Flowers and AdoreMe, today ... Recommendations and Replenishment. Using Optimove,s machine learning algorithms, ... product and replenishment recommendations to their customers based ... predictions of customer intent drawn from a complex ...
(Date:3/20/2017)... -- At this year,s CeBIT Chancellor Dr. Angela Merkel ... Chancellor came to the DERMALOG stand together with the Japanese Prime Minster ... country. At the largest German biometrics company the two government leaders could ... recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/16/2017)... 16, 2017 CeBIT 2017 - Against identity fraud with DERMALOG solutions ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against ... Used combined in one project, ... ...
Breaking Biology News(10 mins):